RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EPIRUS Biopharmaceuticals Stock

EPIRUS Biopharmaceuticals Equity 2024

EPIRUS Biopharmaceuticals Equity

0 USD

Ticker

EPRSQ

ISIN

US29428P1075

WKN

A117U3

In 2024, EPIRUS Biopharmaceuticals's equity was 0 USD, a 0% increase from the 0 USD equity in the previous year.

EPIRUS Biopharmaceuticals Aktienanalyse

What does EPIRUS Biopharmaceuticals do?

EPIRUS Biopharmaceuticals Inc is an American biotech company specializing in the development of innovative drugs for the treatment of cancer and autoimmune diseases. It was founded in 2010 by Amit Munshi and is headquartered in Boston, Massachusetts. The company's business model is based on the use of biotechnology and advanced research and development to create specialized medications. EPIRUS aims to help patients with serious medical needs and contribute to improving healthcare worldwide. EPIRUS Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing EPIRUS Biopharmaceuticals's Equity

EPIRUS Biopharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding EPIRUS Biopharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating EPIRUS Biopharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

EPIRUS Biopharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in EPIRUS Biopharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about EPIRUS Biopharmaceuticals stock

What is the equity of EPIRUS Biopharmaceuticals this year?

EPIRUS Biopharmaceuticals has equity of 0 USD this year.

What was the equity of EPIRUS Biopharmaceuticals compared to the previous year?

The equity of EPIRUS Biopharmaceuticals has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of EPIRUS Biopharmaceuticals?

A high equity is advantageous for investors of EPIRUS Biopharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of EPIRUS Biopharmaceuticals?

A low equity can be a risk for investors of EPIRUS Biopharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of EPIRUS Biopharmaceuticals affect the company?

An increase in equity of EPIRUS Biopharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of EPIRUS Biopharmaceuticals affect the company?

A reduction in equity of EPIRUS Biopharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of EPIRUS Biopharmaceuticals?

Some factors that can affect the equity of EPIRUS Biopharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of EPIRUS Biopharmaceuticals so important for investors?

The equity of EPIRUS Biopharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can EPIRUS Biopharmaceuticals take to change the equity?

To change equity, EPIRUS Biopharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does EPIRUS Biopharmaceuticals pay?

Over the past 12 months, EPIRUS Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EPIRUS Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EPIRUS Biopharmaceuticals?

The current dividend yield of EPIRUS Biopharmaceuticals is .

When does EPIRUS Biopharmaceuticals pay dividends?

EPIRUS Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EPIRUS Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EPIRUS Biopharmaceuticals located?

EPIRUS Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EPIRUS Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EPIRUS Biopharmaceuticals from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did EPIRUS Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of EPIRUS Biopharmaceuticals in the year 2023?

In the year 2023, EPIRUS Biopharmaceuticals distributed 0 USD as dividends.

In which currency does EPIRUS Biopharmaceuticals pay out the dividend?

The dividends of EPIRUS Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EPIRUS Biopharmaceuticals

Our stock analysis for EPIRUS Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EPIRUS Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.